AcuCort signs Letter of Intent (LOI) with Lunatus for the Middle East and Gulf States

REG

Lunatus is a well-established company with over 20 years of experience representing international healthcare companies in the region, including Abbott Diagnostics and Boston Scientific. The company has a proven track record of successfully introducing and developing profitable pharmaceutical and medical technology brands. Lunatus collaborates with more than 40 global companies and offers a portfolio of 300 product lines.

“This LOI is an important step in our international growth strategy. We see strong potential for Zeqmelit® in the region. Lunatus is a strategic partner, thanks to its strong presence and proven market expertise,” says Jonas Jönmark, CEO of AcuCort.

The parties now intend to finalise negotiations for a commercial agreement during 2025. The objective is to establish Zeqmelit® in several key markets across the region.

About Lunatus
Founded in 2003, Lunatus has formed multiple partnerships with international pharmaceutical companies. The company has a strong track record of successfully launching, building, and maintaining profitable brands.
www.lunatus.com


For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.

 

Datum 2025-06-10, kl 08:30
Källa Cision
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!